Helen Torley Halozyme Therapeutics, Inc. (HALO) insider trading activity

Helen Torley is PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 666,744 shares of HALO, which is worth approximately $35.2 Million. The most recent transaction as insider was on Mar 08, 2023, when has been sold 10,000 shares (Common Stock) at a price of $43.26 per share, resulting in proceeds of $432,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 667K

1.48% 3M change

6.91% 12M change

Total Value Held $35.2 Million

Helen Torley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 08 2023	SELL Open market or private sale	$432,600 $43.26 p/Share	10,000 Reduced 1.58%	623,666 Common Stock
Mar 08 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.55%	633,666 Common Stock
Mar 07 2023	SELL Open market or private sale	$454,700 $45.47 p/Share	10,000 Reduced 1.58%	623,666 Common Stock
Mar 07 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.55%	633,666 Common Stock
Mar 01 2023	SELL Bona fide gift	-	10,000 Reduced 1.58%	623,666 Common Stock
Feb 16 2023	SELL Open market or private sale	$544,864 $49.26 p/Share	11,061 Reduced 1.72%	633,666 Common Stock
Feb 16 2023	BUY Exercise of conversion of derivative security	-	21,010 Added 3.16%	644,727 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$339,086 $49.2 p/Share	6,892 Reduced 1.09%	623,717 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	-	13,092 Added 2.03%	630,609 Common Stock
Feb 12 2023	SELL Payment of exercise price or tax liability	$844,652 $48.92 p/Share	17,266 Reduced 2.72%	617,517 Common Stock
Feb 12 2023	BUY Exercise of conversion of derivative security	-	32,794 Added 4.91%	634,783 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$805,663 $48.92 p/Share	16,469 Reduced 2.66%	601,989 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	31,281 Added 4.81%	618,458 Common Stock
Feb 09 2023	SELL Open market or private sale	$504,000 $50.4 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock
Feb 08 2023	SELL Open market or private sale	$513,600 $51.36 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Feb 08 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock
Feb 07 2023	SELL Open market or private sale	$512,600 $51.26 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Feb 07 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock
Jan 19 2023	SELL Open market or private sale	$524,099 $52.41 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Jan 19 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock
Jan 18 2023	SELL Open market or private sale	$510,500 $51.05 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Jan 18 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock
Jan 17 2023	SELL Open market or private sale	$506,700 $50.67 p/Share	10,000 Reduced 1.67%	587,177 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	$146,600 $14.66 p/Share	10,000 Added 1.65%	597,177 Common Stock

Also insider at

DGX

QUEST DIAGNOSTICS INC Healthcare

Director

Helen Torley

PRESIDENT AND CEO

Secaucus, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account